03-02-2025 | Breast Cancer | Research
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study
Authors:
M. Jogendran, J. A. Flemming, M. Djerboua, M. Korzeniowski, B. E. Wilson, S. J. Merchant, S. Bennett
Published in:
Breast Cancer Research and Treatment
Login to get access
Abstract
Background
The association between cirrhosis and post-operative breast cancer outcomes has not been explored. We evaluated the association between cirrhosis and surgical outcomes in female patients with breast cancer.
Methods
We performed a retrospective population-based cohort study of female patients undergoing surgery for breast cancer between 2007 and 2018 using health administrative data from Ontario, Canada. Patients were stratified by cirrhosis status. Overall survival (OS) was described using the Kaplan–Meier method and the association between cirrhosis and long-term cancer-specific mortality (CSM) was evaluated using adjusted competing risks regression and subdistribution hazard ratios (sHR).
Results
A total of 902 patients with breast cancer and cirrhosis were compared to 81,514 patients with breast cancer without cirrhosis. The median age at diagnosis was 65 years vs 61 years in patients with and without cirrhosis, respectively (p < .001). The most common etiologies of cirrhosis were metabolic dysfunction-associated steatotic liver disease (n = 595, 66%) and alcohol-associated (n = 143, 16%) liver disease. The median model for end-stage liver disease sodium score was 8 (IQR 6–11, n = 215). Furthermore, cirrhosis was associated with a twofold higher 90-day rate of post-operative mortality (RR 2.82; 95% CI 1.49–5.33). OS was lower in patients with cirrhosis (HR 1.41, 95% CI 1.26–1.58); however, there was no association with CSM (sHR 1.11, 95% CI 0.93–1.32).
Conclusion
This large population-based study demonstrates that patients with cirrhosis have lower OS compared to those without cirrhosis; however, there is no difference in CSM. Their outcomes remain favorable, and they should be considered for curative-intent therapies.